Stem cell-derived exosomes for regenerative medicine

A UK biotech company is learning how to mass-produce microscopic biological parcels that could one day replace living stem cells in regenerative medicine. ReNeuron already has a stem cell therapy for stroke and limb ischaemia in clinical trials. But those cells also release tiny sacs called exosomes, which carry proteins and genetic material between cells. In lab models, these exosomes shrink glioblastoma tumours—an aggressive brain cancer with few treatment options. The problem is that exosomes are difficult to purify in large, consistent batches at a cost that makes clinical use viable. This project tackles that manufacturing bottleneck. If the team can develop a scalable, cost-effective purification method and complete the preclinical safety and efficacy studies needed for a clinical trial application, the exosomes could become a new class of off-the-shelf regenerative medicine. Unlike living cells, exosomes have a long shelf-life and do not require cold-chain storage, making them easier to distribute to hospitals. Success would open a faster, cheaper route to treating glioblastoma and potentially other diseases, while strengthening the UK’s regenerative medicine manufacturing base.